Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vapitadine in chronic idiopathic urticaria
2005-002749-38Phase 2Completed
- Sponsor
- Barrier Therapeutics, Inc.
- Start
- Mar 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic idiopathic urticaria (CIU) comparing vapitadine 60 mg o.d with placebo (2 arms). Primary endpoint: Change in average itch severity score over one week relative to baseline. Started Mar 2006; status: completed.
02
Drugs
vapitadine
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2005-002749-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002749-38.